What is Cue Biopharma?
, a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 34.69M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 414,075 shares $389k | 0 |
| 3-6months | 1172,715 shares $2.0M | 0 |
| 6-9months | 0 | 0 |
| 9-12months | 0 | 5323,857 shares $100k |